90Y Ibritumomab Tiuxetan (Zevalin) Combined With BEAM (Z -BEAM) Conditioning Regimen Plus Autologous Stem Cell Transplantation in Relapsed or Refractory Low-grade CD20-positive B-cell Lymphoma. A GELA Phase II Prospective Study-Reference-Cited by-同舟云学术

90Y Ibritumomab Tiuxetan (Zevalin) Combined With BEAM (Z -BEAM) Conditioning Regimen Plus Autologous Stem Cell Transplantation in Relapsed or Refractory Low-grade CD20-positive B-cell Lymphoma. A GELA Phase II Prospective Study

Published:2011-04 Issue:2 Volume:11 Page:212-218
ISSN:2152-2650
Container-title:Clinical Lymphoma Myeloma and Leukemia
language:en
Short-container-title:Clinical Lymphoma Myeloma and Leukemia

Author:

Decaudin Didier,Mounier Nicolas,Tilly Hervé,Ribrag Vincent,Ghesquières Hervé,Bouabdallah Krimo,Morschhauser Franck,Coiffier Bertrand,Le Gouill Steven,Bologna Serge,Delarue Richard,Huynh Anne,Bosly André,Brière Josette,Gisselbrecht Christian

Funder

Bayer Schering Pharma AG

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference37 articles.

1. Phase I/II 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma;Wiseman;Eur J Nucl Med,2000

2. Long-term responses in patients with recurring or refractory B-cell non-Hodgkin's lymphoma treated with yttrium 90 ibritumomab tiuxetan;Witzig;Cancer,2007

3. Efficacy and safety of yttrium-90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for autologous stem-cell transplantation;Morschhauser;Blood,2007

4. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma;Witzig;J Clin Oncol,2002

5. Phase II trial of short-course CHOP-R followed by 90Y-ibritumomab tiuxetan and extended rituximab in previously untreated follicular lymphoma;Jacobs;Clin Cancer Res,2008

Cited by 48 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Theranostics of Hematologic Disorders;Nuclear Medicine and Immunology;2021-11-25

2. Bendamustine as part of conditioning of autologous stem cell transplantation in patients with aggressive lymphoma: a phase 2 study from the GELTAMO group;British Journal of Haematology;2018-12-12

3. Recent advances in treating extra-ocular lymphomas;Expert Review of Ophthalmology;2018-07-04

4. Radioimmunotherapy-based conditioning regimen prior to autologous stem cell transplantation in non-Hodgkin lymphoma;International Journal of Hematologic Oncology;2018-03-01

5. Clinical Use and Efficacy of Ibritumomab in B Cell Lymphoma;Resistance to Targeted Anti-Cancer Therapeutics;2018